The value of a specialist lipid clinic

International Journal of Clinical Practice

Volumn 62, Issue 6, 2008, Pages 961-966

  Martin, S C ^a   Viljoen, A ^b  

^a PETERBOROUGH CITY HOSPITAL   (United Kingdom)

^b MOUNT VERNON CANCER CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BEZAFIBRATE; EZETIMIBE; FENOFIBRATE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; DRUG COST; FEMALE; GLUCOSE TOLERANCE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

AMBULATORY CARE; AMBULATORY CARE FACILITIES; CARDIOVASCULAR DISEASES; DRUG COSTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LIPID METABOLISM; TREATMENT OUTCOME;

EID: 43749112529     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01667.x     Document Type: Article

References (35)

1. Murray CJL, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997 349 : 1498 504.
2. Petersen S, Peto V, Scarborough P, Rayner M. Coronary Heart Disease Statistics. London : BHF, 2005.
3. JBS 2: Joint British Societies guidelines on the prevention of cardiovascular disease in clinical practice. Heart 2005 91 : 1 52.
4. Expert Panel on Detection, Evaluation, Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001 285 : 2486 97.
5. International Atherosclerosis Society. Harmonized Clinical Guidelines on the Prevention of Atherosclerotic Cardiovascular Disease. http://www.athero.org/ download/guidelines.pdf (accessed August 2006).
6. General Medical Services Contract. http://www.nhsconfed.org/docs/ contract.pdf (accessed August 2006).
7. de Lusignan S, Dzregah H, Hague N, Chan T. Cholesterol management in patients with IHD: an audit-based appraisal of progress towards clinical targets in primary care. Br J Cardiol 2003 10 : 223 8.
8. Davidson MH. Differences between clinical trial efficacy and real-world effectiveness. Am J Manag Care 2006 12 : S405 11.
9. Davidson MH, Maki KC, Pearson TA et al. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol 2005 96 : 556 63.
10. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ 1996 312 : 71 2.
11. Scally G, Donaldson LJ. Clinical governance and the drive for quality improvement in the new NHS in England. BMJ 1998 317 : 61 5.
12. Carlisle D. Payment by results. How crude tariffs are getting under the skin of specialists. Health Serv J 2007 117 : 14 5.
13. Smith J, Dixon J, Mays N et al. Practice based commissioning: applying the research evidence. BMJ 2005 331 : 1397 9.
14. Liu JL, Maniadakis N, Gray A, Rayner M. The economic burden of coronary heart disease in the UK. Heart 2002 88 : 597 603.
15. Fidan D, Unal B, Critchley J, Capewell S. Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000-2010. Q J Med 2007 100 : 277 89.
16. Evans GR, Taylor G, Taylor KG. The work of a lipid clinic: an audit of performance. Q J Med 1990 74 : 239 45.
17. Anderson KM, Odell PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991 121 : 293 8.
18. Bayly GR, Bartlett WA, Davies PH et al. Laboratory-based calculation of coronary heart disease risk in a hospital diabetic clinic. Diabet Med 1999 16 : 697 701.
19. National Institute for Clinical Excellence. Guidance TA94 Cardiovascular Disease - statins: 2006. http://guidance.nice.org.uk/TA94/guidance/pdf/English (accessed September 2007).
20. Patel JV, Kirby M, Hughes EA. The lipid audit: analysis of lipid management in two centres in Britain 2003. Br J Cardiol 2004 11 : 214 7.
21. The National Service Framework for Coronary Heart Disease - Modern Standards and Service Models. London : Department of Health, 2000.
22. NHS Executive. SMAC statement on the use of statins, executive letter EL(97)41. Wetherby, West Yorkshire : Department of Health, 1997.
23. Quality and Outcomes Framework Database. http://www.gpcontract.co.uk/ pctarea.php?orgcode=5JW&area=1&year=5 (accessed September 2007) P, Wilson K, Dimoules P, Mills ES. Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. BMC Public Health 2006 6 : 300.
24. Bloomgarden ZT. Insulin resistance, dyslipidemia, and cardiovascular disease. Diabetes Care 2007 30 : 2164 70.
25. Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2002 48 : 436 72.
26. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe: glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria: the DECODE study group. Lancet 1999 354 : 617 21.
27. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study. Diabetes Care 1999 22 : 920 4.
28. Nissen SE, Tuzcu EM, Schoenhagen P et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. JAMA 2004 291 : 1071 80.
29. Crouse JR, Raichlen JS, Riley WA et al. Effect of Rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: The METEOR trial. JAMA 2007 297 : 1344 53.
30. Bucher HC, Griffith LE, Guyatt GH. Systematic review on the risk and benefit of different cholesterol-lowering interventions. Arterioscler Thromb Vasc Biol 1999 19 : 187 95.
31. National Institute for Clinical Excellence. Final appraisal determination Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia: Sept 2007. http://www.nice.org.uk/nicemedia/pdf/ EzeFADtoPMforappeal.pdf (accessed November 2007).
32. Athyros VG, Giouleme OI, Nikolaidis NL et al. Long-term follow-up of patients with acute hypertriglyceridemia-induced pancreatitis. J Clin Gastroenterol 2002 34 : 472 5.
33. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systematic review. JAMA 2007 298 : 786 98.
34. Nissen SE, Tardif J-C, Nicholls SJ et al. Effect of torcetrapib on the progression of coronary atherosclerosis. NEJM 2007 356 : 1304 16.
35. Kapp MB. Patient autonomy in the age of consumer-driven health care: informed consent and informed choice. J Leg Med 2007 28 : 91 117.